NasdaqCM:CORTPharmaceuticals
Corcept Therapeutics (CORT) Dropped, So What Is Behind The Latest Attention?
Corcept Therapeutics (CORT) is back in focus after regulators in Europe moved its lead oncology asset a step closer to potential approval for platinum-resistant ovarian cancer, following supportive late-stage clinical data.
Short term, the share price has cooled, with Corcept Therapeutics down 3.98% over the last session and 8.89% over 30 days. However, a 38.02% 90 day share price return and 188.72% year to date share price gain sit alongside a 5 year total shareholder return of 443.57%,...